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Summary
 
We evaluated mature peripheral blood eosinophils for their expression of the surface tyrosine
kinase, c-
 
kit
 
, the receptor for the stromal cell–derived cytokine, stem cell factor (SCF). Cyto-
fluorographic analysis revealed that c-
 
kit
 
 was expressed on the purified peripheral blood eosino-
phils from 8 of 8 donors (4 nonatopic and 4 atopic) (mean channel fluorescence intensity 2.0–
3.6-fold, average 2.8 
 
6
 
 0.6-fold, greater than the negative control). The uniform and selective
expression of c-
 
kit
 
 by eosinophils was confirmed by immunohistochemical analysis of periph-
eral blood buffy coats. The functional integrity of c-
 
kit
 
 was demonstrated by the capacity of
100 ng/ml (5 nM) of recombinant human (rh) SCF to increase eosinophil adhesion to 3, 10,
and 30 
 
m
 
g/ml of immobilized FN40, a 40-kD chymotryptic fragment of plasma fibronectin, in
15 min by 7.7 
 
6
 
 1.4-, 5.3 
 
6
 
 3.3-, and 5.4 
 
6
 
 0.2-fold, respectively, and their adhesion to 0.1, 0.5,
and 1.0 
 
m
 
g/ml vascular cell adhesion molecule-1 (VCAM-1), by 12.7 
 
6
 
 9.2-, 3.8 
 
6
 
 2.5-, and
1.7 
 
6
 
 0.6-fold, respectively. The SCF-stimulated adhesion occurred without concomitant changes
in surface integrin expression, thereby indicating an avidity-based mechanism. rhSCF (100 ng/ml,
5 nM) was comparable to rh eotaxin (200 ng/ml, 24 nM) in stimulating adhesion. Cell adhe-
sion to FN40 was completely inhibited with antibodies against the 
 
a
 
4
 
 and 
 
b
 
1
 
 integrin subunits,
revealing that the SCF/c-
 
kit
 
 adhesion effect was mediated by a single integrin heterodimer,
very late antigen 4 (VLA-4). Thus, SCF represents a newly recognized stromal ligand for the activa-
tion of eosinophils for VLA-4–mediated adhesion, which could contribute to the exit of these
cells from the blood, their tissue localization, and their prominence in inflammatory lesions.
 
E
 
osinophils are bone marrow–derived granulocytes with
a dominant extravascular distribution primarily in mu-
cosal tissues (1, 2). Eosinophils have been implicated bene-
ficially in host defense against helminthic parasitic infection
(3–6), in anti-tumor cytotoxicity (7–9), and in wound heal-
ing (10, 11). Conversely, the abundant eosinophils in the
respiratory mucosal tissue from patients with asthma or
rhinitis are believed to contribute to the inflammatory pro-
cess by releasing preformed, highly cationic granule proteins
with cytotoxic effects (12) and by generating lipid media-
tors, in particular the cysteinyl leukotriene, leukotriene C
 
4
 
,
with attendant vascular and bronchial smooth muscle con-
strictor action (13). Eosinophils at the foci of tissue inflam-
mation bear membrane markers of activation such as CD69
(14, 15) and exhibit extended survival, which is attributed
to the attenuation of apoptosis by hematopoietic cytokines,
particularly IL-5, and GM-CSF (16, 17).
Integrins, heterodimeric cell surface receptors, partici-
pate in the regulation of leukocyte endothelial cell adhe-
sion, transendothelial cell/basement membrane migration,
and localization in inflammatory tissues. Eosinophils express
the very late antigen (VLA)
 
1
 
-4 (
 
a
 
4
 
b
 
1
 
) and VLA-6 (
 
a
 
6
 
b
 
1
 
) as
well as 
 
a
 
4
 
b
 
7
 
 (18–20). VLA-4 mediates leukocyte attach-
ment to VCAM-1 on activated endothelial cells (18, 21).
Anti-
 
a
 
4
 
 antibodies block eosinophil recruitment and pre-
vent antigen-induced bronchial hyperreactivity in several
animal models, suggesting a critical role for the 
 
a
 
4
 
 integrins
 
1
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,7
 
9
 
-bis-(2-carboxyethyl)-
5-(and 6)-carboxyfluorescein acetoxymethyl ester; BMMC, bone mar-
row–derived mast cells; CS-1, connecting segment-1; HSA, human se-
rum albumin; MACS, magnetic cell separation; MFI, mean fluorescence
intensity; rh, recombinant human; SCF, stem cell factor; VCAM, vascular
cell adhesion molecule; VLA, very late antigen.
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in the tissue recruitment, activation, and/or accumulation
of eosinophils in allergic disease (22–26). The VLA-4 inte-
grin also binds to fibronectin through an alternatively
spliced connecting segment-1 (CS-1) region of fibronectin
(27). The interaction between VLA-4 and fibronectin re-
sults in prolonged eosinophil survival in culture by induc-
ing the autocrine generation of GM-CSF and IL-3 (28).
Inasmuch as a subpopulation of eosinophils in nasal polyps
(29) and bronchoalveolar lavage fluid from individuals with
asthma undergoing allergen challenge (30) expresses GM-
CSF protein and/or mRNA, it is possible that in situ VLA-
4–fibronectin interaction prolongs eosinophil retention and
viability through an autocrine mechanism.
Stem cell factor (SCF, also known as steel factor) is a bone
marrow stromal cytokine central to hematopoiesis (31–33).
It is also a peripheral tissue product of fibroblasts and en-
dothelial cells (34–37). SCF exists in two different forms,
soluble and membrane bound, and is the ligand for the c-
 
kit
 
receptor that is found on primitive hematopoietic cells (38).
Among hematopoietic cells, c-
 
kit
 
 is believed to be retained
only by mature tissue mast cells, and thus is a commonly
used marker for the latter (39, 40). Interaction of the c-
 
kit
 
receptor with SCF stimulates the growth and early differ-
entiation of hematopoietic cells (38) and sustains mast cell
growth and differentiation in cultures of mouse bone mar-
row (41, 42) and human cord blood (43, 44). In response
to cross-linking of the high affinity IgE receptor, Fc
 
e
 
R1,
SCF primes mature dispersed human lung mast cells for both
augmented exocytosis of secretory granules (45) and cyto-
kine production (46) and primes mouse bone marrow–
derived mast cells (BMMC) for enhanced generation of
membrane-derived eicosanoids (47). Additionally, SCF is a
direct activator of BMMC, stimulating both exocytosis and
eicosanoid generation with the same biochemical steps and
kinetics as activation by Fc
 
e
 
R1 (48). SCF promotes the ad-
hesion of BMMC to fibronectin via 
 
b
 
1
 
 integrins, increasing
the 
 
a
 
5
 
b
 
1
 
 (VLA-5) integrin avidity (49–51). Thus, SCF is a
potentially critical regulatory factor in the localization, pro-
liferation, priming, and direct activation of mast cells.
We now demonstrate by cytofluorographic and immuno-
histochemical analyses the surface expression of c-
 
kit
 
 receptor
in freshly isolated peripheral blood human eosinophils.
That recombinant human (rh)SCF augments eosinophil adhe-
sion to the VLA-4 ligands, fibronectin, and VCAM-1, estab-
lishes the functional integrity of the eosinophil-expressed c-
 
kit
 
.
Thus, SCF represents an abundant stromal ligand with direct
activating effects for human eosinophils as well as mast cells.
 
Materials and Methods
 
Reagents and Antibodies.
 
rhSCF (catalogue no. 1833-01, lot
no. B6326; Genzyme, Cambridge, MA), rh eotaxin (Endogen,
Inc., Boston, MA), 2
 
9
 
,7
 
9
 
-bis-(2-carboxyethyl)-5-(and-6)-carboxy-
fluorescein acetoxymethyl ester (BCECF-AM) (Molecular Probes,
Eugene, OR), human serum albumin (HSA) (Sigma Chem. Co.,
St. Louis, MO), purified anti-human c-
 
kit
 
 YB5.B8 (PharMingen,
San Diego, CA), purified anti-human c-
 
kit
 
 (95C3) (Coulter, Mi-
ami, FL), purified anti-human integrin 
 
b
 
1
 
 (CD29) (4B4) (Coul-
 
ter), purified anti-human integrin 
 
a
 
4
 
 (CD49d) (A4-PUJ1) (Up-
state Biotechnology, Lake Placid, NY), purified anti-human CD3
(HIT3a) (PharMingen), mouse laminin and the 40-kD chymo-
tryptic fragment of human fibronectin (FN40) (GIBCO BRL,
Gaithersburg, MD) were purchased. The preparation of purified
VCAM-(mouse C
 
k
 
) fusion protein (VCAM-1-
 
k
 
) was previously
reported (52). Anti-human integrin 
 
a
 
4
 
 (CD49d) (B5G10, ascites)
(53), anti-human integrin 
 
a
 
6
 
 (CD49f) (450-33D, ascites) (54),
anti-human integrin 
 
b
 
1
 
 (CD29) (A-1A5, ascites) (55), purified anti-
human integrin 
 
a
 
4
 
b
 
7
 
 (Act-1) (56), and the negative control anti-
body P3 (hybridoma culture supernatant) (57) were provided by
Dr. M.E. Hemler (Dana-Farber Cancer Institute, Harvard Medi-
cal School). Purified anti-human c-
 
kit
 
 mAb SR-1 (ascites) (58) was a
gift from Dr. V. Broudy (University of Washington, Seattle, WA).
 
Isolation of Eosinophils from Peripheral Human Blood.
 
Blood was
collected into sterile, heparinized syringes from the peripheral veins
of nonatopic and atopic volunteer donors who gave informed con-
sent. After the erythrocytes were sedimented with dextran for 45
min at 37
 
8
 
C, the granulocyte fraction was obtained by centrifuga-
tion through a cushion of Ficoll–Hypaque (1.77 g/ml; Pharma-
cia, Uppsala, Sweden) of the buffy coat at 350 
 
g
 
 for 30 min. After
the hypotonic lysis of residual erythrocytes, eosinophils were sep-
arated from neutrophils by negative immunomagnetic selection with
a magnetic cell separation (MACS) column (Miltenyi Biotec, Sun-
nyvale, CA) (59). In brief, the erythrocyte-depleted granulocyte
pellet was incubated for 45 min at 4
 
8
 
C with anti-CD16 mAb
bound to immuno-magnetic beads. When the mixture was ap-
plied to a steel wire column in a strong magnetic field, the
CD16
 
1
 
 neutrophils were retained, whereas the CD16
 
2
 
 eosino-
phils were highly purified in the fraction that flowed through the
column. Contaminating T lymphocytes and monocytes were fur-
ther removed by incubating the CD16
 
2
 
 fraction for another 15
min at 4
 
8
 
C with saturating concentrations of anti-CD3 and anti-
CD14 magnetic beads, respectively (Miltenyi). Cytocentrifuga-
tion slides of the eosinophils stained with Wright’s and Giemsa
stains showed that the purity of the isolated eosinophils was
greater than 95% in all experiments.
 
Cytofluorographic and Immunohistochemical Analyses of Surface c-kit
Expression on Eosinophils.
 
Cytofluorographic analyses of surface
epitopes expressed by human peripheral blood eosinophils with or
without rhSCF stimulation were performed by established proce-
dures (52). Freshly isolated human peripheral blood eosinophils were
resuspended in RPMI 1640 medium containing 10% FCS at a
concentration of 10
 
6
 
 cells/ml and were divided into two identical
fractions. rhSCF was added to one fraction to a final concentra-
tion of 100 ng/ml (5 nM). Alternatively, rh eotaxin was used at a
final concentration of 24 nM and both fractions were incubated
for 15 min at 37
 
8
 
C. The cells were harvested and washed once with
cold PBS containing 0.5% HSA and 0.02% sodium azide (FACS
buffer). Samples of 5 
 
3
 
 10
 
5
 
 cells were then incubated for 1 h on ice
with primary antibodies (purified mAbs at a final concentration of
10 
 
m
 
g/ml or ascites at a final dilution of 1
 
;
 
500 or P3 culture su-
pernatant at 1
 
;
 
4 dilution). The cells were washed once with
FACS buffer and incubated in the dark for 1 h on ice with fluo-
rescein isothiocyanate–conjugated goat anti–mouse IgG (GIBCO
BRL) at a final dilution of 1
 
;
 
100. The cells were washed again
with the FACS buffer, resuspended in 0.25 ml of PBS, and ana-
lyzed on a FACSort
 
Ò
 
 machine (Becton Dickinson, Oxnard, CA).
For c-
 
kit
 
 expression (Fig. 1), the results are presented as overlaid
histograms and the fold increase of mean fluorescence intensity
(MFI). The fold increase of c-
 
kit
 
 expression was calculated by di-
viding the MFI units of SR-1 staining by the MFI units of P3
control mAb staining in each donor. 
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For immunohistochemical analysis of the surface c-
 
kit
 
 expres-
sion, peripheral blood buffy coats were prepared after dextran
sedimentation of erythrocytes. Two fractions of the buffy coat,
each containing 10
 
6
 
 white blood cells, were incubated on ice for
1 h with SR-1 (1
 
;
 
500 diluted ascites) and control P3 antibody (1
 
;
 
4
diluted hybridoma culture supernatant) in a total volume of 100 
 
m
 
l
of FACS buffer, respectively. Cells were washed once with 3 ml
of FACS buffer, and cytocentrifugation slides were prepared, with
4 
 
3
 
 10
 
4
 
 cells per slide. The slides were fixed in 4% paraformalde-
hyde (Polysciences, Inc., Warrington, PA) in PBS for 10 min at
room temperature. After washing with PBS for 3–4 times, the
slides were blocked with 2% chicken egg albumin (Sigma) for 30
min at room temperature, and were incubated with 1
 
;
 
10 diluted
goat anti–mouse IgG(Fc)-conjugated gold particles (average size
10 nm) (Amersham International, Buckinghamshire, England) for
1 h at room temperature. The slides were washed first with PBS
2–3 times and then with distilled water 2–3 times. A silver en-
hancement procedure was carried out for 8 min at room tempera-
ture following the manufacturer’s manual (AuroProbe
 
Ô
 
; Amer-
sham). The slides were then counterstained with hematoxylin and
eosin, mounted with Permount
 
Ò
 
 (Fisher Scientific, Pittsburgh,
PA), and analyzed with a Leica microscope (Model Dialux 20).
Results were photographically recorded using Kodak Royal Gold
film ASA25.
 
Cell Adhesion Assay.
 
Cells were attached in stasis to FN40,
VCAM-1, and laminin as described (52). FN40 and laminin at con-
centrations of 3 
 
m
 
g/ml, 10 
 
m
 
g/ml, and 30 mg/ml were coated
onto non–tissue culture grade 96-well microtiter plates (Nunc-
Immuno Plate) in 0.1 M NaHCO3 (pH 8.3) (100 ml/well) for 16 h
at 48C. The plates were washed twice with PBS (150 ml/well),
and the nonspecific binding sites were blocked by incubation
with 5% HSA in PBS (100 ml/well) for 45 min at 378C. After
two washes with PBS (150 ml/well), the plates were ready to be
used. For the VCAM-1 assay, plates were precoated with goat
anti–mouse k (GIBCO BRL) at a 1;1,000 final dilution in 0.1 M
NaHCO3 (100 ml/well) for 16 h at 48C. After two washes with
PBS, the plates were coated with VCAM-1-k at concentrations
of 0.1, 0.5, and 1.0 mg/ml in 0.1 M NaHCO3 (100 ml/well) for
2 h at 48C. The plates were washed with PBS and blocked with
HSA as mentioned above. The freshly isolated eosinophils were
incubated with BCECF-AM (5 mg/ml) in RPMI 1640 containing
10 mM Hepes and 0.1% HSA (RPMI–HSA) for 30 min at 378C,
washed twice with PBS, and resuspended in RPMI–HSA at 4 3
106 cells/ml. Samples (50 ml) of the cell suspension containing
2 3 105 cells were added to each well of the ligand-coated plate;
each well had been preloaded with either 50 ml of RPMI–HSA or
50  ml of RPMI–HSA containing defined concentrations of
rhSCF (generally 10 nM) or defined concentrations of rh eotaxin
(generally 48 nM). The plates were incubated for 15 min at 378C,
and the fluorescence of total input cells was quantitated by a fluo-
rescence analyzer (Idexx Laboratories, Westbrook, ME). Un-
bound cells were removed by washing the plates with RPMI/10
mM Hepes 4–5 times at 150 ml/well until the cells in the control
wells (5% HSA alone) were less than 5% of their total input. Cells
remaining attached to the plate were quantitated after every wash
with the same fluorescence analyzer. The percentage of specific
binding to immobilized integrin ligands was calculated as the flu-
orescence of the cells detected after the final wash divided by the
fluorescence of the total starting cells 3 100, and assay results are
presented as means 6 SD of three independent experiments, each
performed in triplicate.
For antibody-blocking experiments, cells were resuspended in
cold RPMI–HSA at a concentration of 4 3 106 cells/ml and di-
vided into four identical lots. Purified mAbs were added to each
lot to a final concentration of 10 mg/ml. The mAbs used in this
study were anti-CD3 (negative control), anti-a4 (A4-PUJ1), anti-
a4b7 (Act-1), and anti-b1 (4B4). Cells were incubated with the
mAbs for 10 min on ice and added to each well of a FN40 (30
mg/ml) coated plate. During the 15-min incubation at 378C, the
mAb concentration in each well was reduced to 5 mg/ml by pre-
loading the wells with RPMI–HSA with or without rhSCF or rh
eotaxin. The remainder of the assay procedure was as described
above.
Statistical Analysis. The statistical significance of differences
between sample means for each set of cells was based on compar-
ison as determined by the Student’s t test for matched pairs. Re-
sults are presented as mean 6 SD.
Results
Cytofluorographic and Immunohistochemical Analyses of Sur-
face c-kit Expression on Eosinophils. To determine whether
freshly isolated, peripheral human blood eosinophils ex-
pressed the c-kit receptor, the purified cells from eight sep-
Figure 1. Cytofluorographic analysis of c-kit receptor expression on
freshly isolated, human peripheral blood eosinophils. (A) Eosinophils from
donors 1 and 2 were analyzed with three different mouse anti–human c-kit
mAbs, SR-1 (—— ), YB5.B8 (----), and 95C3 (.....), as well as a control
mouse mAb, P3 (——), (IgG control). (B) Eosinophils from an additional
6 donors (3–8) were analyzed with SR-1 and P3 mAbs. The values ex-
pressed on the y axis are values of the MFI units of SR-1 staining divided
by the MFI units of P3 control mAb staining in each donor.316 Functional c-kit Receptor on Eosinophils
arate donors (four nonatopic and four atopic) were ana-
lyzed by cytofluorography for the expression of c-kit. Three
mouse mAbs against three independent epitopes of the hu-
man c-kit (58, 60) gave virtually identical expression for
two of the donors (Fig. 1 A), with mean log fluorescence
intensities of 2.0- and 3.3-fold over control, respectively,
with mAb SR-1. The surface c-kit expression was subse-
quently confirmed in six additional donors with one of the
three mAbs, SR-1 (Fig. 1 B). In every case, the c-kit ex-
pression was readily detectable, with a mean log fluores-
cence intensity of 2.0 to 3.6-fold greater than the negative
control (IgG control mAb P3) (mean 2.8 6 0.6 fold, n 5 8).
To confirm c-kit expression by peripheral blood eosino-
phils and determine its potential expression by other circu-
lating leukocytes, peripheral blood buffy coats from two
separate donors (1 atopic and 1 nonatopic) were incubated
with either SR-1 or control P3 antibody, and were sub-
jected to immunohistochemical analysis using secondary
antibody-conjugated gold particles and a silver enhance-
ment procedure, followed by counterstaining with hema-
toxylin and eosin. As indicated by the counterstaining and
shown for the nonatopic donor (Fig. 2), 100% of the eosin-
ophils in the buffy coats were positive for c-kit, and eosino-
phils were the only cells displaying a signal for c-kit recep-
tor. Identical results were obtained for the atopic donor
(data not shown). A similar positive signal was also detected
on freshly isolated human peripheral blood eosinophils after
MACS column purification (data not shown).
Effect of rhSCF on Eosinophil Adhesion to FN40 and
rVCAM-1. To determine the functional integrity of the
expressed c-kit receptor on eosinophils, the ability of
rhSCF to augment their adhesion to ligands selective for
integrin a4 and a6 was evaluated in a static adhesion assay.
The 15-min time course for the adhesion assay was selected
because a kinetic study showed that augmented adhesion
peaked at 15 min, persisted for 30 min, and decreased to base-
line by 45 min (data not shown). Adhesion to FN40 increased
at all three inputs of 3, 10, and 30 mg/ml of immobilized
FN40. In the absence of rhSCF, the adhesion of FN40 was
limited (specific binding of 4.3 6 3.5% at 30 mg/ml
FN40). Concomitant stimulation with rhSCF (5 nM) aug-
mented adhesion to 3, 10, and 30 mg/ml FN40 by 7.7 6
1.4-fold, 5.3 6 3.3-fold, and 5.4 6 0.2-fold, respectively,
compared with baseline (Fig. 3). Adhesion to rVCAM-1 also
increased in relation to the input of ligand. In the absence
of rhSCF, rVCAM-1 supported greater adhesion than
FN40 (specific binding of 9.3 6 9% and 22.5 6 10% at 0.5
mg/ml and 1.0 mg/ml of rVCAM-1, respectively). Stimu-
lation with rhSCF augmented adhesion to 0.1, 0.5, and 1.0
mg/ml rVCAM-1 by 12.7 6 9.2-fold, 3.8 6 2.5-fold, and
1.7 6 0.6-fold, respectively, compared with baseline (Fig. 3).
Higher baseline adhesion mediated by VCAM-1 compared
with fibronectin has been previously reported (22). Cell ad-
hesion to laminin also increased in a dose-dependent fash-
ion with respect to ligand input but did not increase further
with stimulation by rhSCF (Fig. 3). Treatment with rhSCF
did not change the surface expression of integrin a4, a6, b1,
a4b7, or c-kit receptor as evaluated by cytofluorographic anal-
ysis (Fig. 4), indicating that the increases in adhesion to the
a4 ligands were not due to increased receptor expression.
Effect of Antibody Neutralization on rhSCF-stimulated Adhe-
sion of Eosinophils to FN40. Both of the a4 integrins ex-
pressed on eosinophils, VLA-4 (a4b1) and a4b7, serve as re-
ceptors for FN40 and VCAM-1 (19). Antibody-blocking
experiments were performed in the assay for adhesion of
eosinophils to 30 mg/ml FN40 with or without rhSCF
stimulation (5 nM). Although the fold increase in response
to rhSCF was similar at each concentration of FN40 (see
Fig. 3), the greatest absolute increment in adhesion oc-
curred at 30 mg/ml FN40. mAbs against a4 (A4-PUJ1) and
b1 (4B4) completely abolished eosinophil adherence to FN40,
whereas the anti-a4b7 mAb (Act-1) had no effect and was
comparable to the control mAb of irrelevant specificity
(anti-CD3) (Fig. 5). Similarly, cell adhesion to rVCAM-1
Figure 2. Immunohistochemical
analysis of c-kit receptor expression
on freshly prepared human periph-
eral blood buffy coats. Peripheral
blood buffy coats were incubated
with either negative control mAb
P3 (IgG matched) (a), or anti-
human c-kit mAb SR-1 (b), and
cytocentrifugation slides were
prepared. After application of sec-
ondary antibody-conjugated gold
particles and a silver enhancement
procedure, the slides were counter-
stained with hematoxylin and eosin,
and analyzed with a Leica micro-
scope. Arrows indicate the eosino-
phils. Other leukocytes, as shown
in the same field, were negative for
surface c-kit expression. Higher
magnification views of individual
eosinophils are shown in the upper
right corners.317 Yuan et al.
in the absence or presence of rhSCF (5 nM) was also com-
pletely blocked by anti-a4 and anti-b1 mAbs (data not
shown). Therefore, rhSCF–c-kit ligation specifically aug-
mented the adhesion of VLA-4 to its ligands, fibronectin,
and VCAM-1.
Dose Effect of rhSCF on Eosinophil Adhesion to FN40.
The effect of rhSCF at concentrations ranging from 12.5
ng/ml (0.625 nM) to 200 ng/ml (10 nM) on eosinophil ad-
hesion to 30 mg/ml FN40 was studied. Enhancement of
VLA-4 binding to FN40 by rhSCF was significant at 2.5, 5,
and 10 nM as compared with the unstimulated replicate
eosinophils (P ,0.05) (Fig. 6). Each fourfold increment in
rhSCF concentration produced a statistically significant
gain in binding (P ,0.05) except for the final increment
between 2.5 and 10 nM, suggesting that a plateau was
reached.
Comparison of the Effects of rhSCF and rh Eotaxin on Eo-
sinophil Binding to FN40. Eotaxin, a selective eosinophil
chemoattractant (61, 62), belongs to the CC chemokine
family. Other members of this family are known to be
stimuli for eosinophil adhesion via integrin a4 (63). Prelim-
inary dose-dependence experiments indicated that the ef-
fect of 24 nM rh eotaxin was similar to the effect of 5 nM
rhSCF for augmenting eosinophil adhesion to 30 mg/ml
FN40. Thus, the effects of these concentrations on eosino-
phil adhesion were compared over three concentrations of
FN40 (Fig. 7). Eotaxin at 24 nM increased eosinophil bind-
ing to FN40 to the same extent as 100 ng/ml (5 nM) rhSCF
at each static input of FN40 ligand. Eotaxin did not change
the surface expression of c-kit, a4, a6, b1, and a4b7 by
cytofluorographic analysis (data not shown), and the aug-
mented adhesion of these cells to FN40 produced by eo-
taxin was completely blocked by mAbs against a4 and b1
(Fig. 8).
The dose-related effect of rh eotaxin on human eosino-
Figure 3. Effect of rhSCF on
the adhesion of human eosino-
phils to FN40, VCAM-1, and
laminin. Freshly isolated, human
peripheral blood eosinophils
were incubated for 15 min at
378C in 96-well plates coated
with FN40, VCAM-1, or lami-
nin (LN) in the presence (j) or
absence of (h) rhSCF (100 ng/
ml, 5 nM) and assayed for adhe-
sion. Data are presented as mean
6 SD of three independent ex-
periments for FN40 and LN and
four independent experiments
for VCAM-1, each performed
in triplicate. Asterisks indicate
P  ,0.05.
Figure 4. Cytofluorographic analysis of the effect of rhSCF (100 ng/ml)
on c-kit and integrin expression by eosinophils after incubation for 15 min
at 378C. Values on the x axis are the MFI units of each mAb staining.
Data are presented as mean 6 SD of MFI units from three independent
donors. Medium alone (h); medium plus rhSCF (j).
Figure 5. Effect of rhSCF on the adhesion of human eosinophils to
FN40 (30 mg/ml) in the presence of anti-integrin mAbs and control IgG
mAb. Isolated human eosinophils were incubated with mouse anti–human
a4 (A4-PUJ1), anti-human a4b7 (Act-1), anti-human b1 (4B4), or IgG
control mAb anti-human CD3 (HIT3a) for 10 min at 48C before being
assayed for adhesion with or without rhSCF (100 ng/ml, 5 nM) in 96-
well plates coated with FN40 (30 mg/ml) for 15 min at 378C. Data are
presented as mean 6 SD of three independent experiments each per-
formed in triplicate.318 Functional c-kit Receptor on Eosinophils
phil adhesion to FN40 (30 mg/ml) was analyzed in the ab-
sence and presence of 1.25 nM rhSCF. The approximate
EC50 for rh eotaxin-augmented adhesion occurred at the
lowest concentration studied, 3 nM, and the plateau was
reached at 12 nM (20.8 6 13-fold, n 5 3). The effect of
the concomitant presence of rhSCF at slightly less than its
EC50 (see Fig. 6) was generally somewhat additive and did
not extend the maximum reached with the plateau doses of
rh eotaxin alone (Fig. 9).
Discussion
The finding that mature human peripheral blood eosino-
phils express a functional c-kit receptor for SCF reveals that
Figure 6. Dose effect of rhSCF on eosinophil adhesion to FN40. Hu-
man eosinophils were assayed for adhesion to FN40 (30 mg/ml)–coated
96-well plates in the presence of increasing concentrations of rhSCF. Data
are presented as mean 6 SD of three independent experiments each per-
formed in triplicate. Single asterisk indicates significant stimulation relative
to the unstimulated eosinophils and double asterisk indicates significant
stimulation relative to a fourfold lesser concentration.
Figure 8. Effect of rh eotaxin on the adhesion of human eosinophils to
FN40 (30 mg/ml) in the presence of anti-integrin mAbs and control IgG
mAb. Isolated human eosinophils were incubated with mouse anti–human a4
(A4-PUJ1), anti–human a4b7 (Act-1), anti–human b1 (4B4) or IgG con-
trol mAb anti–human CD3 (HIT3a) for 10 min at 48C before being as-
sayed for adhesion with or without rh eotaxin (24 nM) in 96-well plates
coated with FN40 (30 mg/ml) for 15 min at 378C. Data are presented as
mean 6 SD of three independent experiments, each performed in triplicate.
Figure 7. Comparison of the effects of rhSCF and eotaxin on eosino-
phil adhesion to FN40. Human eosinophils were assayed for adhesion to
FN40-coated 96-well plates for 15 min at 378C in medium alone (h) or in
the presence of rhSCF (100 ng/ml, 5 nM) (j) or rh eotaxin (24 nM)
( ). Data are presented as mean 6 SD of three independent experiments
each performed in triplicate.
Figure 9. Effects of the combination of rhSCF and rh eotaxin on the
adhesion of human eosinophils to FN40. Human eosinophils were as-
sayed for adhesion to FN40 (30 mg/ml)–coated 96-well plates in the pres-
ence of increasing concentrations of rh eotaxin, either alone (h) or with a
constant dose of rhSCF (25 ng/ml, 1.25 nM) (j). Data are presented as
mean 6 SD of three independent experiments, each performed in triplicate.319 Yuan et al.
a stromal ligand can activate effector cells conventionally
linked to allergic inflammation. Although originally appre-
ciated for its central role in the hematopoiesis of all lin-
eages, SCF is elaborated in the peripheral microenviron-
ment by diverse cell types, including endothelial cells and
fibroblasts (34–37). In addition to the functional implica-
tions for eosinophil- and mast cell–directed inflammation,
the study also uncovers a potential limitation to the use of
c-kit detection as a marker of mature mast cells.
In the initial experiments, the surface expression of the
c-kit receptor was established by cytofluorographic analysis
of freshly isolated human peripheral blood eosinophils. The
expression was similar among the cells of all eight donors
tested (Fig. 1), irrespective of the presence of donor atopy
by history. To exclude an unsuspected specificity, three
mAbs directed against separate epitopes of the human c-kit
were shown to yield nearly identical fluorescence signals.
The positive surface c-kit expression was also demonstrated
by immunohistochemical analysis of peripheral blood buffy
coats (Fig. 2). Eosinophils were uniformly positive for c-kit
expression and were the only cell type expressing c-kit in
these preparations. The presence of c-kit was then con-
firmed by the functional, dose-related response of the eosin-
ophils to SCF signal in static adhesion assays (Fig. 6). An
earlier study did not detect a c-kit signal on peripheral
blood eosinophils, and functional assays with SCF were not
performed (64). However, this same study did demonstrate
low level c-kit expression by human peripheral blood baso-
phils and a priming effect of SCF on their IgE-dependent
release of histamine (64). Because eosinophils and basophils
are closely related and arise from a common progenitor
(65), the expression of c-kit and their activation via SCF
can now be added to the list of their shared characteristics.
Moreover, a triad of hematopoietic allergic effector cells,
mast cells, basophils, and eosinophils, would appear to share
the expression of c-kit.
rhSCF–c-kit stimulated eosinophil adhesion to FN40
and VCAM-1, but not to laminin (Fig. 3), implying a re-
sponse via an a4 integrin. Antibody-blocking studies re-
vealed that the adhesion of eosinophils to FN40 (Fig. 5)
and VCAM-1 (data not shown) was mediated by VLA-4
without the involvement of a4b7. Because the surface inte-
grin receptor numbers were unchanged after treatment of
the cells with rhSCF, including a4, a6, b1, and a4b7 (Fig.
4), the enhanced adhesiveness of VLA-4 induced by rhSCF
was likely due to increased avidity of VLA-4 to its ligands.
This observation is supported by an earlier study with the
transformed human cell line MO7E (66). The a4b7 inte-
grin did not contribute to the fibronectin and VCAM-1
binding, suggesting that the avidity change of VLA-4 by
SCF may be conveyed through either the unique b subunit
or the combined effect on the a and b heterodimer. The
fact that rhSCF did not increase VLA-6 (a6b1)–mediated
adhesion to laminin favors the latter hypothesis. Thus, the
SCF–c-kit engagement on human peripheral blood eosino-
phils provides an inside–out signal to increase transiently
the avidity of an integrin, VLA-4, for its cell surface and
matrix ligands.
Recently, Weber and colleagues (63) demonstrated that
the CC chemokines RANTES and MCP-3, as well as the
anaphylatoxin C5a, rapidly increased a4 integrin avidity on
eosinophils and augmented their adhesion to VCAM-1 and
fibronectin with a peak at 15 min after stimulation. This re-
sult prompted us to examine the effect of another CC
chemokine, eotaxin, on eosinophil adhesive function. The
EC50 values of 1.25–2.5 nM for rhSCF (Fig. 6) and of 3
nM for rh eotaxin (Fig. 9) were similar with 30 mg/ml of
FN40. Similarly, the magnitudes of eosinophil binding to
the inputs of 3, 10, and 30 mg/ml of FN40 were similar at
the plateau concentrations of rhSCF and of rh eotaxin (Fig.
7). The cell adhesion response to each stimulus (rhSCF and
rh eotaxin) for the ligand FN40 depended entirely on VLA-4,
as shown by mAb inhibition (Figs. 5 and 8). Stimulation of
the peripheral blood eosinophils with less than the EC50 for
the stromal cytokine, rhSCF, and incremental amounts of
the chemokine, rh eotaxin, appeared additive, and the com-
bination neither increased the maximal cellular response nor
revealed a negative counterregulatory action for the com-
mon target, VLA-4.
Cell migration is a complex process requiring constant
changes of the cell-substratum bonds with formation of new
bonds (adhesion) at the leading edge of a cell and break-
down of old bonds (deadhesion) at the rear of the cell (67).
This transient response is essential for adhesion to be fol-
lowed by random or directed cell migration. Progressive
movement within a tissue may require integrated activation
of one integrin and resultant negative regulation of another
integrin on the same cell as the ligand binding requirements
change. For example, in Chinese hamster ovary cells, en-
gagement of the transfected human aIIbb3 with its specific
ligand caused a transdominant inhibition of other integrins
and resulted in suppressed adhesion of endogenous hamster
a5b1 to fibronectin, as well as transfected human a2b1 to
collagen (68). In another study, the activation of the trans-
fected integrin aIIbb3 in Chinese hamster ovary cells, detected
by mAb PAC1 binding, was suppressed by the introduction
of H-Ras and Raf-1 to these cells (69). This suppressive ac-
tivity was correlated with activation of the ERK MAP ki-
nase pathway and did not involve other dual specificity kinase
sequences such as SEK–c-Jun or MKK–p38 MAP kinase
(69). Thus, the activation of a particular integrin by cyto-
kines such as SCF, which leads to an enhanced binding of
that integrin to its ligand, may contribute to an integrated
signal for coordinated cellular events such as cell migration.
Although found in small numbers in the circulation of
healthy people, eosinophils mainly reside in the mucosal
tissues in vivo, with an estimated tissue;circulation ratio of
200;1 (1). The mechanisms involving the tissue-specific
localization of eosinophils are not commonly addressed, as
most studies have focused on the incremental recruitment
with immunologically elicited inflammation. SCF is a nor-
mal constitutive product of endothelial cells and fibroblasts
and can be detected in the serum (36, 70). Therefore, it is a
candidate to mediate a basal level interaction between cir-
culating eosinophils and endothelial cells by facilitating in-
teraction between VLA-4 and VCAM-1 at very low levels320 Functional c-kit Receptor on Eosinophils
of VCAM-1 expression (71). Alternatively, exposure of
eosinophils to SCF in the extracellular matrix may mediate
their transient attachment to fibronectin, altering their mi-
gration speed and influencing their tissue localization. In-
deed, Palecek and colleagues (72) have demonstrated that
at low concentrations of ligand, cell migration speed in-
creased as integrin binding affinity increased. Thus, SCF is
a candidate for participating in the tissue distribution of
eosinophils under normal physiologic conditions.
The interaction of VLA-4 and VCAM-1 plays a key role
in lymphocyte and eosinophil adhesion and extravasation in
both in vitro and in vivo models of allergic inflammation
(18, 22–26). VCAM-1 expression is upregulated in the
eosinophil-rich, inflamed airway tissue of individuals with
asthma (73, 74). VLA-4 is expressed on eosinophils and
lymphocytes, but not neutrophils; and the c-kit receptor
expression is limited to eosinophils among these three cell
types. Thus, under conditions of allergic inflammation, lo-
cal SCF could contribute both by priming mast cells to
elaborate IL-4 (46, 75) and TNF-a (75) with consequent
upregulation of endothelial cell VCAM-1 expression (76),
and by mediating a transiently increased avidity for that
ligand by eosinophil VLA-4. This possibility is supported
by a recent finding in mice of the association of allergen
challenge-induced eosinophilic airways inflammation with
increased levels of histamine and SCF in bronchoalveolar
lavage fluid and of SCF in serum (70). In that study, the ad-
ministration of antibody to SCF before allergen challenge
markedly decreased histamine release and pulmonary eosin-
ophil infiltration. The inflammatory response induced by
allergen challenge also increases the production of the eosin-
ophil-selective chemoattractant, eotaxin (61), which is a prod-
uct of a number of cell types including epithelial cells, en-
dothelial cells, fibroblasts, and even eosinophils (62). Therefore,
increased concentrations of eotaxin and SCF could provide
a coordinated signal for the selective recruitment of eosino-
phils, beginning with transiently enhanced eosinophil adhe-
sion to endothelial cells within the vasculature through
VLA-4–VCAM-1 interaction, followed by directed tissue
movement through adhesion/deadhesion in a chemotactic
gradient, and final eosinophil tissue retention through regu-
lated integrin–matrix interaction. Such a matrix interaction
may also prolong eosinophil survival through autocrine pro-
duction of IL-3 and GM-CSF initiated by VLA-4–fibro-
nectin interaction (28).
We have provided evidence that SCF is an agonist for
eosinophil adhesion. These findings have potential rele-
vance for physiologic eosinophil trafficking and for allergic
inflammation, in which mast cell activation and eosinophil
accumulation are both prominent features.
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